| Re: Актовегин, церебролизин и др. |
Заголовок темы: Re: Актовегин, церебролизин и др. Отправитель: Dr.Admin 2008/1/16 23:33:11 ОК. Для осторого периода после ЧМТ - церебролизин не годен. Допустим. А вот, нагпример, для Альцгеймера? Некотрые работы, связанные с церебролизином и б-ю Альцгеймера Навскидку, только с www.alzforum.org Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006 May 15;83 (7):1252-61. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24- week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006 Jan 1;13(1):43-54. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm. 2005 Feb 1;112(2):269-82. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. The neuroprotective effects of Cerebrolysin trade mark in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm. 2003 Nov ;110(11):1313-27. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol (Berl). 2003 Mar ;105 (3):225-32. Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer's disease: a randomized, double- blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm. 2002 Jul ;109(7-8):1089-104. Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002 ;:277-85. Ruether E, Alvarez XA, Rainer M, Moessler H. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double- blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002 ;:265-75. Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z, Winterer W, Koper D, Kasper S, Rainer M, Moessler H. A 28-week, double- blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol. 2001 Sep ;16(5):253-63. Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc. 2000 Dec 1;48 (12):1566-71. Molloy DW, Standish TI. Clinical experience with Cerebrolysin. J Neural Transm Suppl. 2000;59:293-300 Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000;107(7):815-29. Veinbergs I, Mante M, Mallory M, Masliah E. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl. 2000;59:273-80. Lombardi VR, Windisch M, Garcia M, Cacabelos R. Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol. 1999 Jun;21(5):331-8. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav. 1999 Feb;62(2):239-45. Funke M, Fiehler J, Mewes I, Eiselt M, Rother I, Windisch M. Dose-dependent effects of Cerebrolysin on EEG and short- term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl. 1998;53:385-98. Schwab M, Schaller R, Bauer R, Zwiener U. Morphofunctional effects of moderate forebrain ischemia combined with short- term hypoxia in rats--protective effects of Cerebrolysin. Exp Toxicol Pathol. 1997 Feb;49(1-2):29-37. Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, Kotlan P, Paulitsch G, Reiner C, Stossl J, Zachhuber C, Mossler H. Therapeutic results with Cerebrolysin in the treatment of dementia. Wien Med Wochenschr. 1997;147(18):426-31. Francis-Turner L, Valouskova V. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett. 1996 Jan 5;202(3):193-6. Есть еще ряд работ, посвященных инсультам... Теоретически, если сложить первое и второе... Собственно, в чем же будет контртезис? В том, что низкомолекулярные пептиды/дериваты нуклеиновых кислот -не работают вообще -не работают при заболеваниях x, y, z... -недостаточно изучены и потому опасны и непредсказуемы -не применяются в стране a, b (причина: опасны, неизучены, иное) а потому не должны применятся у нас -иное ? |
| |учеба|публикации участников|библиотека| |